Monoclonal antibodyFDA-approvedSecond-line
Panitumumab
How it works
Panitumumab targets the epidermal growth factor receptor (EGFR) on cancer cells, blocking the growth signal and leading to cell death.
Cancer types
Colorectal Cancer— Wild-type KRAS
Efficacy
Studies show that panitumumab can improve overall survival and progression-free survival in patients with metastatic colorectal cancer and wild-type KRAS, with median survival ranging from 12 to 20 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Pancreatic Cancer Trial Examines Chemotherapy with or without Panitumumab | Pancreatic Cancer | phase-3 | — | Source → |
| Panitumumab-IRDye800 Trial for Pancreatic Cancer Patients Undergoing Surgery | Pancreatic Cancer | phase-1 | — | Source → |
| Early Magnesium Supplementation Helps Manage Hypomagnesemia in Colorectal Cancer Patients | Colorectal Cancer | observational | The incidence of grade 3 or higher hypomagnesemia was significantly lower in the post-protocol group than in the pre-protocol group (3.3% vs. 30.0%). | Source → |
| New Cancer Treatment Shows Promise in Advanced Colorectal Cancer | Colorectal Cancer | phase-3 | The overall response rates were 30.2% for sotorasib 960 mg-panitumumab, 7.5% for sotorasib 240 mg-panitumumab, and 1.9% for investigator's choice. | Source → |
| New Combination Therapy Shows Promise in Treating Colorectal Cancer | Colorectal Cancer | phase-2 | Preliminary results demonstrate significant improvements in progression-free survival (PFS) and objective response rates. | Source → |
| Adding Panitumumab to Chemotherapy for Colon Cancer | Colorectal Cancer | phase-2 | There was a trend towards reduced recurrences with FOLFOX plus panitumumab compared with FOLFOX (12% versus 21%, hazard ratio = 0.51, P = 0.09) | Source → |
| Comparing Two Cancer Treatments in Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | There was no significant difference in median overall survival between treatment groups (9.1 months vs 10.1 months). | Source → |
| Combining Chemotherapy and Anti-EGFR Antibody May Help Some Colorectal Cancer Patients | Colorectal Cancer | meta-analysis | The pooled objective response rate was 85% (95% CI, 0.78-0.91; I = 58%) and the pooled rate of R0 resection was 42% (95% CI, 0.32-0.53; I = 62%). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.